Literature DB >> 25593119

Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor.

Mika Naganawa1, Ming-Qiang Zheng2, Shannan Henry2, Nabeel Nabulsi2, Shu-Fei Lin2, Jim Ropchan2, David Labaree2, Soheila Najafzadeh2, Michael Kapinos2, Johannes Tauscher3, Alexander Neumeister4, Richard E Carson2, Yiyun Huang2.   

Abstract

UNLABELLED: (11)C-LY2795050 is a new antagonist PET radioligand for the κ opioid receptor (KOR). In this study, we assessed the reproducibility of the binding parameters of (11)C-LY2795050 in healthy human subjects.
METHODS: Sixteen healthy subjects (11 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free fraction (fP) measurements. The 2-tissue-compartment model and multilinear analysis-1 were applied to calculate 5 outcome measures in 14 brain regions: distribution volume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total plasma concentration, and binding potential relative to free plasma concentration: BPND, BPP, BPF, respectively). Since KOR is distributed ubiquitously throughout the brain, there are no suitable reference regions. We used a fixed fraction of individual cerebellar VT value (VT,CER) as the nondisplaceable VT (VND) (VND = VT,CER/1.17). The relative and absolute test-retest variability and intraclass correlation coefficient were evaluated for the outcome measures of (11)C-LY2795050.
RESULTS: The test-retest variability of (11)C-LY2795050 for VT was no more than 10% in any region and was 12% in the amygdala. For binding potential (BPND and BPP), the test-retest variability was good in regions of moderate and high KOR density (BPND > 0.4) and poor in regions of low density. Correction by fP (VT/fP or BPF) did not improve the test-retest performance.
CONCLUSION: Our results suggest that quantification of (11)C-LY2795050 imaging is reproducible and reliable in regions with moderate and high KOR density. Therefore, we conclude that this first antagonist radiotracer is highly useful for PET studies of KOR.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  brain imaging; kappa opioid receptor; positron emission tomography; test–retest reproducibility

Mesh:

Substances:

Year:  2015        PMID: 25593119      PMCID: PMC4322754          DOI: 10.2967/jnumed.114.147975

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

Review 2.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

3.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

4.  Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.

Authors:  Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis
Journal:  Synapse       Date:  2006-04       Impact factor: 2.562

5.  Enhancement of MR images using registration for signal averaging.

Authors:  C J Holmes; R Hoge; L Collins; R Woods; A W Toga; A C Evans
Journal:  J Comput Assist Tomogr       Date:  1998 Mar-Apr       Impact factor: 1.826

6.  Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index.

Authors:  Fernando Caravaggio; Sofia Raitsin; Philip Gerretsen; Shinichiro Nakajima; Alan Wilson; Ariel Graff-Guerrero
Journal:  Biol Psychiatry       Date:  2013-03-27       Impact factor: 13.382

Review 7.  Interactions between kappa opioid agonists and cocaine. Preclinical studies.

Authors:  N K Mello; S S Negus
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

8.  Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Authors:  G Gerra; A Fantoma; A Zaimovic
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

9.  Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus.

Authors:  N C de Lanerolle; A Williamson; C Meredith; J H Kim; H Tabuteau; D D Spencer; M L Brines
Journal:  Epilepsy Res       Date:  1997-10       Impact factor: 3.045

10.  11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons.

Authors:  Peter S Talbot; Raj Narendran; Eduardo R Butelman; Yiyun Huang; Kim Ngo; Mark Slifstein; Diana Martinez; Marc Laruelle; Dah-Ren Hwang
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

View more
  19 in total

1.  Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Authors:  Eduardo R Butelman; Bryan D McElroy; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2019-04-11       Impact factor: 4.030

2.  [11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.

Authors:  Francesca Zanderigo; Alexandra E D'Agostino; Nandita Joshi; Martin Schain; Dileep Kumar; Ramin V Parsey; Christine DeLorenzo; J John Mann
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

3.  [11 C]arachidonic acid incorporation measurement in human brain: Optimization for clinical use.

Authors:  Francesca Zanderigo; Yeona Kang; Dileep Kumar; Anastasia Nikolopoulou; P David Mozley; Paresh J Kothari; Bin He; David Schlyer; Stanley I Rapoport; Maria A Oquendo; Shankar Vallabhajosula; J John Mann; M Elizabeth Sublette
Journal:  Synapse       Date:  2017-11-27       Impact factor: 2.562

Review 4.  (11)C[double bond, length as m-dash]O bonds made easily for positron emission tomography radiopharmaceuticals.

Authors:  Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev
Journal:  Chem Soc Rev       Date:  2016-08-22       Impact factor: 54.564

5.  PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo.

Authors:  Aishwarya Vijay; Shuo Wang; Patrick Worhunsky; Ming-Qiang Zheng; Nabeel Nabulsi; Jim Ropchan; Suchitra Krishnan-Sarin; Yiyun Huang; Evan D Morris
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-08-20

6.  Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.

Authors:  Mika Naganawa; Gemma L Dickinson; Ming-Qiang Zheng; Shannan Henry; Francois Vandenhende; Jennifer Witcher; Robert Bell; Nabeel Nabulsi; Shu-Fei Lin; Jim Ropchan; Alexander Neumeister; Mohini Ranganathan; Johannes Tauscher; Yiyun Huang; Richard E Carson
Journal:  J Pharmacol Exp Ther       Date:  2015-12-01       Impact factor: 4.030

7.  Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.

Authors:  Michael S Placzek; Genevieve C Van de Bittner; Hsiao-Ying Wey; Scott E Lukas; Jacob M Hooker
Journal:  Neuropsychopharmacology       Date:  2015-06-10       Impact factor: 7.853

8.  Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates.

Authors:  Songye Li; Zhengxin Cai; Ming-Qiang Zheng; Daniel Holden; Mika Naganawa; Shu-Fei Lin; Jim Ropchan; David Labaree; Michael Kapinos; Teresa Lara-Jaime; Antonio Navarro; Yiyun Huang
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

9.  Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans.

Authors:  Sjoerd J Finnema; Nabeel B Nabulsi; Joël Mercier; Shu-Fei Lin; Ming-Kai Chen; David Matuskey; Jean-Dominique Gallezot; Shannan Henry; Jonas Hannestad; Yiyun Huang; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-09       Impact factor: 6.200

10.  First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer.

Authors:  Mika Naganawa; Nabeel Nabulsi; Shannan Henry; David Matuskey; Shu-Fei Lin; Lawrence Slieker; Adam J Schwarz; Nancy Kant; Cynthia Jesudason; Kevin Ruley; Antonio Navarro; Hong Gao; Jim Ropchan; David Labaree; Richard E Carson; Yiyun Huang
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.